drugset / Trial / NCT07563881

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

NCT07563881 ↗

Phase 3 Recruiting 333 enrolled Rapport Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Timeline

Start
2026-06-05
Primary completion
2029-07
Completion
2029-09

Drugs

EvaluationDrugModalityDoseRoute
Subject RAP-219 Unknown — Oral

Indications